Diabetes, Obesity and Metabolism

1. Diabetes Obes Metab24 Apr 2026

   A Randomized Effectiveness Trial of a Dissonance‐Based Dual Obesity and Eating Disorder Prevention Program

   Randomized controlled trialObesity

2. Diabetes Obes Metab24 Apr 2026

   Continuous Glucose Monitoring in Adults With Diabetes Receiving Haemodialysis: Identifying Dialysis‐Specific Glycaemic Patterns and Associations With Volume Status and Intradialytic Hypoglycaemia

   Cohort studyTechnology

3. Diabetes Obes Metab24 Apr 2026

   Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

   Meta-analysisT2D & other

4. Diabetes Obes Metab23 Apr 2026

   Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

   Research articleObesity

5. Diabetes Obes Metab23 Apr 2026

   Integrated miRNA – mRNA Analysis Reveals Obesity‐Driven Regulatory Networks in Human Visceral Adipose Tissue With and Without Type 2 Diabetes

   Cross-sectional studyObesity

6. Diabetes Obes Metab22 Apr 2026

   Health Care Provider Perceptions of Screening for Early‐Stage Type 1 Diabetes—A Survey Study

   Cross-sectional studyT1D

7. Diabetes Obes Metab22 Apr 2026

   Postprandial Glucagon Action in the Human Brain

   Mechanistic studyT2D & other

8. Diabetes Obes Metab22 Apr 2026

   Integrative Proteomic and Machine Learning Analysis Identifies Novel Predictors and Risk Model for Diabetic Macrovascular Complications

   Diagnostic or prognostic studyComplications

9. Diabetes Obes Metab22 Apr 2026

   Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

   Randomized controlled trialObesity

10. Diabetes Obes Metab22 Apr 2026

    Bifidobacterium bifidum G9‐1 Intake Improves Gastrointestinal Symptoms in Type 2 Diabetes Mellitus: An Open‐Label, Randomized Controlled Trial (Binary STAR Study)

    Randomized controlled trialT2D & other

11. Diabetes Obes Metab20 Apr 2026

    Islet Autoantibodies in Adult With Pituitary and Ovarian Autoimmunity: Implications for Type 1 Diabetes Screening

    Cross-sectional studyT1D

12. Diabetes Obes Metab20 Apr 2026

    Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

    Cohort studyT2D & other

13. Diabetes Obes Metab20 Apr 2026

    Cold‐Induced Lipidomic Remodelling Is Associated With Brown Adipose Tissue Mean Radiodensity in Humans

    Mechanistic studyLipids & liver

14. Diabetes Obes Metab20 Apr 2026

    Discretionary Screen Time and Progression From Prediabetes to Type 2 Diabetes: Mediating Roles of Sleep and the Triglyceride‐Glucose Index

    Cohort studyT2D & other

15. Diabetes Obes Metab20 Apr 2026

    Drug‐Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database

    Cohort studyT1D

16. Diabetes Obes Metab20 Apr 2026

    Higher Body Mass Index Is a Causal Risk Factor for Skin Infections: A Mendelian Randomisation Study Using UK Biobank and FinnGen

    Research articleObesity

17. Diabetes Obes Metab20 Apr 2026

    A Phase 1, Randomised, Double‐Blind, Placebo‐Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP ‐ 1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity

    Randomized controlled trialObesity

18. Diabetes Obes Metab17 Apr 2026

    Effects of Premeal Versus Postmeal Metformin Administration on Postmeal Glycemic Control in Individuals With Type 2 Diabetes Mellitus: A Randomized, 8‐Week Crossover Study

    Randomized controlled trialT2D & other

19. Diabetes Obes Metab17 Apr 2026

    Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials

    Secondary analysisT2D & other

20. Diabetes Obes Metab17 Apr 2026

    Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight

    Research articleObesity

21. Diabetes Obes Metab17 Apr 2026

    Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

    Cohort studyT2D & other

22. Diabetes Obes Metab16 Apr 2026

    Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis

    Meta-analysisObesity

23. Diabetes Obes Metab15 Apr 2026

    GLP ‐1, GIP , and Glucagon Excursions During a Mixed Meal Tolerance Test in Young and Lean South Asians Versus Europids

    Mechanistic studyT2D & other

24. Diabetes Obes Metab15 Apr 2026

    Comparative Predictive Value of Three Visceral Adiposity Indices for Cardiovascular Disease: A 17.5‐Year Korean Cohort Study

    Cohort studyLipids & liver

25. Diabetes Obes Metab14 Apr 2026

    Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

    Cohort studyT2D & other

26. Diabetes Obes Metab13 Apr 2026

    Cardiorenal Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus With Nephrotic‐Range Proteinuria: A Multi‐Institutional Target Trial Emulation

    Cohort studyT2D & other

27. Diabetes Obes Metab13 Apr 2026

    Accuracy of ChatGPT , Gemini, Claude and DeepSeek in Carbohydrate Counting

    Diagnostic or prognostic studyT1D

28. Diabetes Obes Metab13 Apr 2026

    Optimising the Therapeutic Window: A Systematic Review and Network Meta‐Analysis of Pregabalin Dosing Strategies for Painful Diabetic Neuropathy

    Meta-analysisComplications

29. Diabetes Obes Metab13 Apr 2026

    Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

    Cohort studyComplications

30. Diabetes Obes Metab13 Apr 2026

    Insulin Sensitive Patients With Impaired Glucose Tolerance: Physiologic and Metabolic Characterization ( STOP DIABETES )

    Secondary analysisT2D & other

31. Diabetes Obes Metab13 Apr 2026

    Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

    Cohort studyObesity

32. Diabetes Obes Metab13 Apr 2026

    Dietary Fibre, Gut Microbiota and Cardiovascular Outcomes: Differential Associations by Diabetes Status in Multiethnic Cohorts

    Cohort studyT2D & other

33. Diabetes Obes Metab13 Apr 2026

    Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model

    Cohort studyT2D & other

34. Diabetes Obes Metab13 Apr 2026

    Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study

    Cohort studyT2D & other

35. Diabetes Obes Metab13 Apr 2026

    Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP ‐1 Receptor Agonists: A Meta‐Analysis and Meta‐Regression of Randomised Controlled Trials

    Meta-analysisT2D & other

36. Diabetes Obes Metab13 Apr 2026

    Nutrition and Exercise: A Scoping Review of Best Practices for Addressing Social Determinants of Health in the Management of Type 2 Diabetes

    Research articleT2D & other

37. Diabetes Obes Metab8 Apr 2026

    Pathway‐Specific Polygenic Risk Scores and Cardiorenal Complications in Asians With Type 2 Diabetes

    Cohort studyComplications

38. Diabetes Obes Metab8 Apr 2026

    Longitudinal Associations Between Weight‐Adjusted Waist Index and Cognition in Middle‐Aged and Older Adults in China

    Cohort studyObesity

39. Diabetes Obes Metab7 Apr 2026

    Diabetes Mellitus and Early Antiplatelet Treatment for Minor Stroke Following Intravenous Thrombolysis: Prespecified Secondary Analysis of the EAST Trial

    Secondary analysisT2D & other

40. Diabetes Obes Metab7 Apr 2026

    Real‐World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido‐ TZP Study

    Cohort studyT2D & other

All 2,200 Briefs in ExploreShowing Briefs 441–480 of 2,200, newest first